scholarly journals Intensified intravitreal bevacizumab treatment regime for type 1 and 2 idiopathic macular telangiectasia

2016 ◽  
Keyword(s):  
Intravitreal Bevacizumab ◽  
Treatment Regime ◽  
Macular Telangiectasia ◽  
Bevacizumab Treatment ◽  
Idiopathic Macular Telangiectasia

scholarly journals Intravitreal Bevacizumab Treatment in Type 2 Idiopathic Macular Telangiectasia

2016 ◽  
Vol 46 (6) ◽  
pp. 270-273 ◽  
Author(s):  
Tuğba Aydoğan ◽  
Gürkan Erdoğan ◽  
Cihan Ünlü ◽  
Ahmet Ergin
Keyword(s):  
Intravitreal Bevacizumab ◽  
Macular Telangiectasia ◽  
Bevacizumab Treatment ◽  
Idiopathic Macular Telangiectasia

scholarly journals Macular Oedema in Idiopathic Macular Telangiectasia Type 1 Responsive to Aflibercept but Not Bevacizumab

2014 ◽  
Vol 2014 ◽  
pp. 1-4 ◽  
Author(s):  
O’Sam Shibeeb ◽  
Anagha Vaze ◽  
Mark Gillies ◽  
Timothy Gray
Keyword(s):  
Macular Oedema ◽  
Laser Photocoagulation ◽  
Intravitreal Bevacizumab ◽  
Argon Laser ◽  
Macular Telangiectasia ◽  
Argon Laser Photocoagulation ◽  
Intravitreal Aflibercept ◽  
Idiopathic Macular Telangiectasia ◽  
The Right

We report a patient with macular oedema due to type 1 macular telangiectasia responding to intravitreal aflibercept injection. A 51-year-old man was diagnosed with type 1 idiopathic macular telangiectasia (IMT) in the right eye. The macular oedema was refractory to initial treatment with intravitreal bevacizumab and argon laser photocoagulation. The patient was then treated with intravitreal aflibercept injections, following which the macular oedema was completely resolved and his vision was significantly improved. Intravitreal aflibercept injection appears to improve vision and reduce persistent macular oedema secondary to type 1 IMT and demonstrated promising anatomical and visual outcomes.

scholarly journals Intravitreal bevacizumab for type 1 idiopathic macular telangiectasia

Eye ◽  
2010 ◽  
Vol 24 (9) ◽  
pp. 1492-1497 ◽  
Author(s):  
K Takayama ◽  
S Ooto ◽  
H Tamura ◽  
K Yamashiro ◽  
A Otani ◽  
...  
Keyword(s):  
Intravitreal Bevacizumab ◽  
Macular Telangiectasia ◽  
Idiopathic Macular Telangiectasia

scholarly journals Multimodal Imaging Findings and Treatment with Dexamethasone Implant in Three Cases of Idiopathic Macular Telangiectasia Type 1

2021 ◽  
pp. 92-97
Author(s):  
Paola Cirafici ◽  
Maria Musolino ◽  
Michela Saccheggiani ◽  
Carlo Enrico Traverso ◽  
Massimo Nicolò
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Multimodal Imaging ◽  
Diagnostic Errors ◽  
Wide Field ◽  
Vascular Changes ◽  
Macular Telangiectasia ◽  
First Choice ◽  
Idiopathic Macular Telangiectasia

This is a report of 3 patients diagnosed with idiopathic macular telangiectasia type 1 (MacTel 1) at Medical Retina Center of the University of Eye Clinic of Genova and then prospectically followed for a mean time of 26 months between 2016 and 2019. It is the first report of patients affected by MacTel 1 treated with dexamethasone (DEX) implant as a first choice of treatment. Aim of our study is to better characterize the disease using a multimodal wide-field imaging and to determine efficacy of DEX implant on MacTel 1 in terms of central macular thickness (CMT) and best-corrected visual acuity (BCVA). MacTel 1 is a rare unilateral disease, characterized by telangiectatic retinal capillaries, cystoid macular edema, and lipid deposition occurring temporal to the fovea. Patients underwent a comprehensive ophthalmic examination, BCVA, swept-source optical coherence tomography (SS-OCT), SS-OCT angiography (SS-OCTA), ultra-widefield (UWF) color, and fluorescein angiography (FA) fundus photograph. All the patients presented monolateral reduced BCVA and macular edema with increased CMT evaluated by SS-OCT. With SS-OCTA, we showed that the telangiectasia-associated vascular changes originate in the deep retinal vascular plexus and as a consequence macular edema and exudation develop causing vision loss. Furthermore, UWF imaging helped us to highlight vascular changes typical of Coats Disease at the far retinal periphery. All the patients were treated with DEX intravitreal implant, showing a decrease in CMT and a stabilization of visual acuity. Due to the recurrent nature of macular edema, patients underwent a mean of 4 DEX implants during the follow-up period. In order to address the clinical features of this uncommon disease avoiding diagnostic errors, it might be important to use a multimodal imaging approach. The anatomical and functional beneficial effects of DEX implant were well evident although transient.

scholarly journals Pars Plana Vitrectomy Combined with Focal Endolaser Photocoagulation for Idiopathic Macular Telangiectasia

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Gaku Terauchi ◽  
Celso Soiti Matsumoto ◽  
Kei Shinoda ◽  
Harue Matsumoto ◽  
Yutaka Imamura ◽  
...  
Keyword(s):  
Fluorescein Angiography ◽  
Pars Plana Vitrectomy ◽  
Late Phase ◽  
Macular Telangiectasia ◽  
Before And After ◽  
Antiangiogenic Drugs ◽  
Pars Plana ◽  
Idiopathic Macular Telangiectasia ◽  
Sd Oct

Background. To report the outcome of pars plana vitrectomy (PPV) combined with intraoperative endolaser focal photocoagulation (PC) on eyes with idiopathic macular telangiectasis (MacTel) type 1.Methods. This was a retrospective study of two female patients with MacTel type 1 who were resistant to focal photocoagulation, sub-Tenon triamcinolone injection, and/or antiangiogenic drugs. The best-corrected visual acuity (BCVA) was determined, and fluorescein angiography (FA) and spectral domain optical coherence tomography (SD-OCT) were performed before and after surgery for up to 19 months.Results. After surgery, the BCVA gradually improved from 20/100 to 20/20 at 19 months in Case 1 and from 20/50 to 20/13 at 13 months in Case 2. Fluorescein angiography (FA) showed leakage at the late phase, and OCT showed that the cystoid macular edema was resolved and the fovea was considerably thinner postoperatively.Conclusion. Patients with MacTel type 1 who are refractory to the other types of treatments can benefit from PPV combined with intraoperative endolaser focal PC with functional and morphological improvements.

Intravitreal Bevacizumab for Type 2 Idiopathic Macular Telangiectasia

2013 ◽  
Vol 49 (4) ◽  
pp. 205-208 ◽  
Author(s):  
Carlos E. Veloso ◽  
Raul N. Vianna ◽  
David E. Pelayes ◽  
Márcio B. Nehemy
Keyword(s):  
Intravitreal Bevacizumab ◽  
Macular Telangiectasia ◽  
Idiopathic Macular Telangiectasia

scholarly journals Response to ‘Bevacizumab and type 1 idiopathic macular telangiectasia’

Eye ◽  
2011 ◽  
Vol 25 (12) ◽  
pp. 1665-1665
Author(s):  
S Ooto ◽  
K Takayama ◽  
N Yoshimura
Keyword(s):  
Macular Telangiectasia ◽  
Idiopathic Macular Telangiectasia
Sign in / Sign up

Export Citation Format

Share Document